Cubist Pharmaceuticals LLC Sustainability Profile
Cubist Pharmaceuticals LLC, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies for infectious diseases. Founded in 1992, the company has achieved significant milestones, including the launch of groundbreaking antibiotics that address critical unmet medical needs. With a strong focus on research and development, Cubist Pharmaceuticals offers a unique portfolio of products designed to combat resistant bacterial infections. Their commitment to advancing healthcare is reflected in their robust pipeline and strategic partnerships within the industry. Recognised for its contributions to public health, Cubist has established a solid market position, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Cubist Pharmaceuticals LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cubist Pharmaceuticals LLC's score of 69 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cubist Pharmaceuticals LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Merck & Co., Inc., and any climate commitments or emissions data may be inherited from this parent organisation. Cubist Pharmaceuticals has not established its own reduction targets or climate pledges. However, it is important to note that the climate initiatives and performance metrics may align with those of Merck & Co., Inc., which is actively engaged in various sustainability efforts. These efforts include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are led by Merck. As a subsidiary, Cubist Pharmaceuticals may benefit from the broader climate strategies implemented by Merck, which include commitments to reduce greenhouse gas emissions across Scope 1, 2, and 3 categories. However, specific details regarding these initiatives and their impact on Cubist's operations are not disclosed. In summary, while Cubist Pharmaceuticals LLC does not provide specific emissions data or reduction targets, it is positioned within a corporate family that is committed to addressing climate change through established initiatives and frameworks.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,532,400,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 5,760,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Cubist Pharmaceuticals LLC's Industry?
How Carbon Intensive is Cubist Pharmaceuticals LLC's Location?
Cubist Pharmaceuticals LLC's Scope 3 Categories Breakdown
Cubist Pharmaceuticals LLC's Scope 3 emissions, which increased by 3% last year and increased by approximately 5% since 2014, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Cubist Pharmaceuticals LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cubist Pharmaceuticals LLC has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Progenics Pharmaceuticals, Inc.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.